Kyntra Bio completes $220M China exit, advances FG-3246 trials; faces Nasdaq delisting risk

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~2 min read

Key Changes

• high

  Company closed sale of China operations to AstraZeneca for $220.4M in August 2025, eliminating going-concern risk and repaying $73.4M term loan. Cash position improved to $100.3M vs $33.6M year-ago.

  MD&A: China Divestiture verify on EDGAR →
• high

  Received Nasdaq deficiency notice in April 2026 for failing $50M asset/revenue requirement due to China operations classified as discontinued. Company has 45 days to submit compliance plan or transfer to Capital Market.

  Risk Factors: Nasdaq Listing verify on EDGAR →
• high

  Phase 2 FG-3246 monotherapy study actively enrolling for mCRPC, interim results expected Q4 2026. UCSF combination study showed 40% response rate in patients progressing on one prior ARSI, median rPFS 10.1 months.

  MD&A: FG-3246 Development verify on EDGAR →